科技圈🎗在花频道📮 | Telegram Webview: TestFlightCN/31944 -

科技圈🎗在花频道📮

过敏性鼻炎治疗研究取得新进展

2025年4月4日，首都医科大学附属北京同仁医院张罗教授团队在国际顶级期刊《自然·医学》（Nature Medicine）发表突破性研究成果——《司普奇拜单抗治疗中重度季节性过敏性鼻炎：一项随机3期试验》（Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial）。
这是全球范围内首次报告基于IL-4Rα靶点的生物制剂治疗季节性过敏性鼻炎的研究成果，亦是中国科学家在过敏性鼻炎领域取得的引领世界的创新性新成果。研究结果显示，司普奇拜单抗能够快速、强效控制患者的鼻部症状，持续显著缓解患者眼部过敏症状，极大提升患者生活质量，且安全性良好。

Nature Medicine

📮投稿 ☘️频道 🌸聊天

www.tg-me.com/us/在花软件新闻投稿频道/com.TestFlightCN/31945

21.2K viewsApr 5 at 12:04

tg-me.com/TestFlightCN/31944

Create: 2025-04-05
Last Update: 2025-04-29 06:11:29

BY 科技圈🎗在花频道📮

Share with your friend now:
tg-me.com/TestFlightCN/31944

在花软件新闻投稿频道 Telegram | DID YOU KNOW?

Telegram Be The Next Best SPAC

I have no inside knowledge of a potential stock listing of the popular anti-Whatsapp messaging app, Telegram. But I know this much, judging by most people I talk to, especially crypto investors, if Telegram ever went public, people would gobble it up. I know I would. I’m waiting for it. So is Sergei Sergienko, who claims he owns $800,000 of Telegram’s pre-initial coin offering (ICO) tokens. “If Telegram does a SPAC IPO, there would be demand for this issue. It would probably outstrip the interest we saw during the ICO. Why? Because as of right now Telegram looks like a liberal application that can accept anyone - right after WhatsApp and others have turn on the censorship,” he says.

Importantly, that investor viewpoint is not new. It cycles in when conditions are right (and vice versa). It also brings the ineffective warnings of an overpriced market with it.Looking toward a good 2022 stock market, there is no apparent reason to expect these issues to change.